One of the most innovative methods for treating cancer is CAR T-cell therapy. This novel immunotherapy fights cancer by utilizing the patient’s immune system. For patients who have not responded to traditional treatments for a variety of hematologic malignancies, such as various types of leukemia and lymphoma, CAR T-cell therapy has demonstrated exceptional potential as a game-changing therapeutic alternative.
According to SPER Market Research, ‘Global CAR T-Cell Therapy Market Size- By Drug Type, By Indication, By End User – Regional Outlook, Competitive Strategies and Segment Forecast to 2033’ states that the Global CAR T-Cell Therapy Market is estimated to reach USD 46.23 billion by 2033 with a CAGR of 28.78%.
Drivers:
One of the major factors positively affecting the market expansion for CAR-T cell treatment is the notable increase in the prevalence of cancer worldwide. Additionally, the increasing availability of Patient Assistance Programs (PAPs) is driving the adoption of this therapy. Furthermore, governments everywhere are acting to raise awareness of cancer, which is promoting the market’s growth.
Additionally, the growing incidence of cancer is one of the primary factors driving market expansion. According to WHO estimates, there were around 20 million new cases of cancer and 9.7 million deaths from the disease globally in 2022. There were an estimated 53.5 million persons who were still alive five years after being diagnosed with cancer.
Restraints:
One of the biggest issues facing the CAR T-cell therapy sector is recruiting patients for clinical trials, which can delay the development and approval of novel therapies. Because of the complexity of CAR T-cell therapy trials, stringent eligibility restrictions, and limited target indications, enrolling enough patients is difficult. A major barrier is the stringent eligibility requirements for CAR T-cell experiments. Often involving specific genetic markers, disease subtypes, and past treatment records, these criteria significantly narrow the pool of eligible patients. Furthermore, the geographic dispersion of people with rare cancers complicates patient recruitment.
In 2020, the COVID-19 pandemic slowed the development of CAR-T cell therapy. The poor diagnostic rate of blood cancer was mostly caused by a number of issues that beset the healthcare system throughout the epidemic. First, the pandemic reduced the frequency of routine medical checks and screenings because many clinics and hospitals delayed unnecessary testing and visits in an effort to reduce the risk of COVID-19 virus transmission.
Request for Free Sample Report @ https://www.sperresearch.com/report-store/car-t-cell-therapy-market.aspx?sample=1
The pandemic also caused supply chain disruptions, which made it challenging for medical professionals to get the supplies and equipment—like imaging devices and blood tests—necessary to detect blood cancer.
Europe dominates the Global CAR T-Cell Therapy Market as the region has high adoption rate of advanced technology and due to the presence of key market players. Major players in the market are Autolus Therapeutics, Bluebird Bio, Inc., Bristol-Myers Squibb, Caribou Biosciences, Inc., Cellectis, Celgene Corporation, Celyad Oncology, Cartesian Therapeutics, Inc.,
CAR T-Cell Therapy Market Segmentation:
By Drug Type: Based on the Drug Type, Global CAR T-Cell Therapy Market is segmented as; Axicabtage Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others.
By Indication: Based on the Indication, Global CAR T-Cell Therapy Market is segmented as; Lymphoma, Acute Lymphocytic Leukemia, Others.
By End User: Based on the End User, Global CAR T-Cell Therapy Market is segmented as; Hospitals, Cancer Treatment Centers.
By Region: This research also include data for North America, Europe, Asia-Pacific Middle East & Africa and South America.
For More Information, refer to below link: –
CAR T-Cell Therapy Market Forecast
Related Reports:
Follow Us –
LinkedIn | Instagram | Facebook | Twitter
Contact Us:
Sara Lopes, Business Consultant – U.S.A.
+1-347-460-2899
